Global Skeletal Dysplasia Market

Global Skeletal Dysplasia Market Size, Trends & Analysis - Forecasts to 2026 By Treatment (Medication, Surgery, Others), By Type (Achondroplasia, X-Linked Hypophosphatemia, Fibrodysplasia ossificans progressive, Hypophosphatasia, Others), By Region (North America, Asia Pacific, CSA, Europe, and the Middle East and Africa); End-User, Landscape, Company Market Share Analysis, and Competitor Analysis

Category Healthcare
Format
  • ms word
  • ms excel
  • ms ppt
  • pdf

Skeletal Dysplasia Market Insights

Skeletal Dysplasia generally occurs in children in which they are born with some abnormal differences from a normal child concerning their physical stature i.e., legs, hands, face, and head, among others, which is also known as dwarfism. It very well may be brought about by various kinds of hereditary transformations, which are passed down from guardians to youngsters. These changes can keep your kid's bones from developing typically. Skeletal dysplasia is also a form of the hereditary disease which can be passed on from one generation to other. The type of skeletal dysplasia occurring the most is achondroplasia which is caused by mutations of a newborn baby's FGFR3 gene. In many of the cases, parents of such children have normal height and stature.

The other types of skeletal dysplasia are thanatophoric dysplasia where the child has very much short limbs along with lungs that are not fully developed, Hypochondroplasia wherein hands and feet are short but broad, Campomelic dysplasia which affects the development of bones and reproductive systems, Osteogenesis imperfecta wherein the bones are so brittle that they can break easily.

There are several treatments for skeletal dysplasia concerning the severity of the condition which can be both surgical and non-surgical. In non-surgical it is bracing, growth hormone therapy, medications, and physical therapy whereas in surgical treatment there are flat foot reconstruction, guided growth for knee bowing, hip or knee reconstruction, spinal decompression, joint replacement, kyphosis correction, and shortening for significant limb length discrepancy.

The occurrence of skeletal dysplasia is 2 to 3 numbers among every 10,000 births across the world and the average cost of a surgical treatment goes up to USD 100000.

The factors driving the skeletal dysplasia market are as follows: Rising cases of birth defects, out of every 5000 newborn babies there is 1 baby born with skeletal dysplasia. Advancement in medical science due to which quite of several treatments are now available for the cure of skeletal dysplasia. Also, pharmaceutical companies are investing huge amounts of money to develop new and better medicines that can cure skeletal dysplasia much more effectively and also are working on cost-effective techniques. Strategies devised by the government to provide treatment for the poor and needy parents who can’t afford treatment for skeletal dysplasia. Bio-technologists coming up with genetic therapy for curing this disease.

Skeletal Dysplasia Market

Skeletal Dysplasia: By Treatment

Based on treatment, the skeletal dysplasia market can be segregated into medication, and surgery, among others. Surgery dominated the market as it is the most preferred type of treatment owing to its efficiency and results. Also due to surgical options, the market of surgical instruments and surgical devices will have a boost in the medical market. Patients' increasing preference for surgeries is expected to be one of the major factors driving the segment growth.

The medication segment is expected to rise the fastest during the forecast era, owing to increased initiatives focusing on producing novel drugs for the treatment of certain forms of skeletal dysplasia, including MO and FPO.

Skeletal Dysplasia: By Type

Based on type, the skeletal dysplasia market can be segregated into achondroplasia, x-linked hypophosphatemia, fibrodysplasia ossificans progressive, and hypophosphatasia, among others. Achondroplasia is the most occurred skeletal dysplasia across the globe as a result a large number of hospitals across the globe have various treatments for this disease. Each hospital or clinic or medical institutions are carrying on their own set of research work which is leading to the growth of this market.

Skeletal Dysplasia Market

Skeletal Dysplasia Market: By Region

North America is dominating this market and will continue the same in the forecast period. Several births with skeletal or any other disorders in the region, awareness from the government regarding the treatment of this disease, government support for people who cannot afford the treatment, and best in class healthcare systems with the world-class surgical facility is driving growth in North America region. Europe is next in the line as they have a good number of biotechnological and research institutions studying and working towards finding a cure for this disease. Apart from this Europe has a non-governmental organization by the name European Skeletal Dysplasia Network whose sole purpose is to study and understand what are the main causes that lead to skeletal dysplasia, work towards an effective diagnosis of this disorder in the region. The Asia Pacific is the fastest-growing market due to the rising number of children that are born with bone deficiency due to lack of calcium supply in their body at the maternity stage.

Skeletal Dysplasia Market Share and Competitor Analysis

BioMarin, Alexion Pharmaceuticals Inc.; Merck KGaA, Amgen Inc.; Regeneron, and Clementia, among others are the top players in the Skeletal Dysplasia Market. 

Please note: This is not an exhaustive list of companies profiled in the report.

In December 2019, recently a genetic testing company Invitae collaborated with BioMarin Pharmaceutical to study skeletal dysplasia as BioMarin is in line to develop medicines for treating skeletal dysplasia by conducting genetic testing on 100+ genes linked to skeletal and bone disorders.

Check the Press Release on Global Skeletal Dysplasia Market Report

Chapter 1   Methodology

1.1    Market Scope & Definitions

1.2    Estimates & Forecast Calculation

1.3    Historical Data Overview And Validation

1.4    Data Sources

1.4.1    Secondary

1.4.2    Primary

Chapter 2   Report Outlook

2.1    Global Skeletal Dysplasia Market Overview, 2019-2026

2.1.1    Industry Overview

2.1.2    Treatment Overview

2.1.3    Type Overview

          2.1.4    Regional Overview

Chapter 3   Global Skeletal Dysplasia Market Trends

3.1    Market Segmentation

3.2    Industry Background, 2019-2026

3.3    Market Key Trends

3.3.1    Positive Trends

3.3.1.1    Technological advancements in medical systems

3.3.1.2    Rising cases of birth defects

3.3.2    Industry Challenges

3.3.2.1    Costly and the myth among people that it is incurable

3.4    Prospective Growth Scenario

3.4.1    Treatment

3.4.2    Type

3.5    COVID-19 Influence over Industry Growth

3.6    Porter’s Analysis

3.7    PESTEL Analysis

3.8    Value Chain & Supply Chain Analysis

3.9    Regulatory Framework

3.9.1    North America

3.9.2    Europe

3.9.3    APAC

3.9.4    LATAM

3.9.5    MEA

3.10    Technology Overview

3.11    Market Share Analysis, 2020

3.11.1    Company Positioning Overview, 2020

Chapter 4   Global Skeletal Dysplasia Market, By Treatment

4.1    Treatment Outlook

4.2    Medication

4.2.1    Market Size, By Region, 2019-2026 (USD Million)

4.3    Surgery

          4.3.1    Market Size, By Region, 2019-2026 (USD Million)

4.4    Others

          4.4.1    Market Size, By Region, 2019-2026 (USD Million)

Chapter 5 Global Skeletal Dysplasia Market, By Type

5.1    Type Channel Outlook

5.2    Achondroplasia

5.2.1    Market Size, By Region, 2019-2026 (USD Million)

5.3    X-Linked Hypophosphatemia

          5.3.1    Market Size, By Region, 2019-2026 (USD Million)

5.4    Hypophosphatasia

          5.4.1    Market Size, By Region, 2019-2026 (USD Million)

5.5    Fibrodysplasia ossificans progressive

          5.5.1    Market Size, By Region, 2019-2026 (USD Million)

5.6    Others

          5.6.1    Market Size, By Region, 2019-2026 (USD Million)

Chapter 6 Global Skeletal Dysplasia Market, By Region

6.1    Regional outlook

6.2    North America

6.2.1    Market Size, By Country 2019-2026 (USD Million)

6.2.2    Market Size, By Treatment, 2019-2026 (USD Million)

6.2.3    Market Size, By Type, 2019-2026 (USD Million)

6.2.4    U.S.

6.2.4.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.2.4.2    Market Size, By Type, 2019-2026 (USD Million)

6.2.5    Canada

6.2.5.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.2.5.2    Market Size, By Type, 2019-2026 (USD Million)

6.3    Europe

6.3.1    Market Size, By Country 2019-2026 (USD Million)

6.3.2    Market Size, By Treatment, 2019-2026 (USD Million)

6.3.3    Market Size, By Type, 2019-2026 (USD Million)

6.3.4    Germany

6.3.4.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.3.4.2    Market Size, By Type, 2019-2026 (USD Million)

6.3.5    UK

6.3.5.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.3.5.2    Market Size, By Type, 2019-2026 (USD Million)

6.3.6    France

6.3.6.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.3.6.2    Market Size, By Type, 2019-2026 (USD Million)

6.3.7    Italy

6.3.7.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.3.7.2    Market Size, By Type, 2019-2026 (USD Million)

6.3.8   Spain

6.3.8.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.3.8.2    Market Size, By Type, 2019-2026 (USD Million)

6.3.9    Russia

6.3.9.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.3.9.2    Market Size, By Type, 2019-2026 (USD Million)

6.4    Asia Pacific

6.4.1    Market Size, By Country 2019-2026 (USD Million)

6.4.2    Market Size, By Treatment, 2019-2026 (USD Million)

6.4.3    Market Size, By Type, 2019-2026 (USD Million)

6.4.4    China

6.4.4.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.4.4.2    Market Size, By Type, 2019-2026 (USD Million)

6.4.5    India

6.4.5.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.4.5.2    Market Size, By Type, 2019-2026 (USD Million)

6.4.6    Japan

6.4.6.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.4.6.2    Market Size, By Type, 2019-2026 (USD Million)

6.4.7    Australia

6.4.7.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.4.7.2    Market size, By Type, 2019-2026 (USD Million)

6.4.8    South Korea

6.4.8.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.4.8.2    Market Size, By Type, 2019-2026 (USD Million)

6.5    Latin America

6.5.1    Market Size, By Country 2019-2026 (USD Million)

6.5.2    Market Size, By Treatment, 2019-2026 (USD Million)

6.5.3    Market Size, By Type, 2019-2026 (USD Million)

6.5.4    Brazil

6.5.4.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.5.4.2    Market Size, By Type, 2019-2026 (USD Million)

6.5.5    Mexico

6.5.5.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.5.5.2    Market Size, By Type, 2019-2026 (USD Million)

6.5.6    Argentina

6.5.6.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.5.6.2    Market Size, By Type, 2019-2026 (USD Million)

6.6    MEA

6.6.1    Market Size, By Country 2019-2026 (USD Million)

6.6.2    Market Size, By Treatment, 2019-2026 (USD Million)

6.6.3    Market Size, By Type, 2019-2026 (USD Million)

6.6.4    Saudi Arabia

6.6.4.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.6.4.2    Market Size, By Type, 2019-2026 (USD Million)

6.6.5    UAE

6.6.5.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.6.5.2    Market Size, By Type, 2019-2026 (USD Million)

6.6.6    South Africa

6.6.6.1    Market Size, By Treatment, 2019-2026 (USD Million)

6.6.6.2    Market Size, By Type, 2019-2026 (USD Million)

Chapter 7 Company Landscape

7.1    Competitive Analysis, 2020

7.2    BioMarin

          7.2.1    Company Overview

7.2.2    Financial Analysis

7.2.3    Strategic Positioning

7.2.4    InfoGraphic Analysis

7.3    Amgen Inc.

7.3.1    Company Overview

7.3.2    Financial Analysis

7.3.3    Strategic Positioning

7.3.4    InfoGraphic Analysis

7.4    Merck KGaA

7.4.1    Company Overview

7.4.2    Financial Analysis

7.4.3    Strategic Positioning

7.4.4    InfoGraphic Analysis

7.5    Regeneron

          7.5.1    Company Overview

7.5.2    Financial Analysis

7.5.3    Strategic Positioning

7.5.4    InfoGraphic Analysis

7.6    Alexion Pharmaceuticals Inc.

7.6.1    Company Overview

7.6.2    Financial Analysis

7.6.3    Strategic Positioning

7.6.4    InfoGraphic Analysis

7.7    Clementia

7.7.1    Company Overview

7.7.2    Financial Analysis

7.7.3    Strategic Positioning

7.7.4    InfoGraphic Analysis  

7.8    Other Companies

7.8.1    Company Overview

7.8.2    Financial Analysis

7.8.3    Strategic Positioning

7.8.4    InfoGraphic Analysis 

The Global Skeletal Dysplasia Market has been studied from the year 2019 till 2026. However, the CAGR provided in the report is from the year 2021 to 2026. The research methodology involved three stages: Desk research, Primary research, and Analysis & Output from the entire research process.

Skeletal Dysplasia Market

The desk research involved a robust background study which meant referring to paid and unpaid databases to understand the market dynamics; mapping contracts from press releases; identifying the key players in the market, studying their product portfolio, competition level, annual reports/SEC filings & investor presentations; and learning the demand and supply-side analysis for the Skeletal Dysplasia Market.

Skeletal Dysplasia Market

The primary research activity included telephonic conversations with more than 50 tier 1 industry consultants, distributors, and end-use product manufacturers.

Skeletal Dysplasia Market

Finally, based on the above thorough research process, an in-depth analysis was carried out considering the following aspects: market attractiveness, current & future market trends, market share analysis, SWOT analysis of the company and customer analytics.

Skeletal Dysplasia Market

We value your investment and offer free customization with every report to fulfil your exact research needs.
This website is secure and your personal details are safe. Privacy

Tailor made solutions just for you

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

OUR CLIENTS

  • Client of Global Market Estimates - Redline Communications
  • Client of Global Market Estimates - Samsung
  • Client of Global Market Estimates - Indorama
  • Client of Global Market Estimates - Horiba
  • Client of Global Market Estimates - Asahi Kasei
  • Client of Global Market Estimates - Lonza
  • Client of Global Market Estimates - Aranca
  • Client of Global Market Estimates - Cablel
  • Client of Global Market Estimates - Carbotainer
  • Client of Global Market Estimates - Chimai
  • Client of Global Market Estimates - Evermore
  • Client of Global Market Estimates - Grapsud
  • Client of Global Market Estimates - infinium
  • Client of Global Market Estimates - Rusada
  • Client of Global Market Estimates - Shield Scientific
  • Client of Global Market Estimates - Signify
  • Client of Global Market Estimates - Teledyne
  • Client of Global Market Estimates - Trelleborg
  • Client of Global Market Estimates - Atlas
  • Client of Global Market Estimates - Bitumar
  • Client of Global Market Estimates - Hidrostal
  • Client of Global Market Estimates - Kikkoman Biochemifa
  • Client of Global Market Estimates - Leoni
  • Client of Global Market Estimates - Medtronic
  • Client of Global Market Estimates - Molnlycke
  • Client of Global Market Estimates - Now-Plastics
  • Client of Global Market Estimates - Playment
  • Client of Global Market Estimates - Spirent
  • Client of Global Market Estimates - Surestar
  • Client of Global Market Estimates - Tokyo Electron Limited
  • Client of Global Market Estimates - Tension Packaging
  • Client of Global Market Estimates - Toray